These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34436547)

  • 1. Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity.
    Schindler TM; Marchington JM; Flores GV
    JAMA Oncol; 2021 Oct; 7(10):1578-1579. PubMed ID: 34436547
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity.
    Stewart DJ; Wheatley-Price P
    JAMA Oncol; 2021 Oct; 7(10):1577-1578. PubMed ID: 34436567
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity.
    Rizzo A; Mollica V; Massari F
    JAMA Oncol; 2021 Oct; 7(10):1577. PubMed ID: 34436578
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity-Reply.
    Del Paggio JC; Eisenhauer EA; Booth CM
    JAMA Oncol; 2021 Oct; 7(10):1579-1580. PubMed ID: 34436516
    [No Abstract]   [Full Text] [Related]  

  • 5. Professional Medical Writer Assistance in Oncology Clinical Trials.
    Kouzy R; Abi Jaoude J; Mainwaring W; Lin TA; Miller AB; Jethanandani A; Espinoza AF; Verma V; Fuller CD; Minsky BD; Rödel C; Taniguchi CM; Ludmir EB
    Oncologist; 2020 Nov; 25(11):e1812-e1815. PubMed ID: 32885898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethics of Pharma Clinical Trials in the Era of Precision Oncology.
    Turner JH
    Cancer Biother Radiopharm; 2021 Feb; 36(1):1-9. PubMed ID: 32935997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials.
    LoRusso PM; Freidlin B
    J Natl Cancer Inst; 2023 Feb; 115(2):122-124. PubMed ID: 36448688
    [No Abstract]   [Full Text] [Related]  

  • 8. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical considerations of neuro-oncology trial design in the era of precision medicine.
    Gupta S; Smith TR; Broekman ML
    J Neurooncol; 2017 Aug; 134(1):1-7. PubMed ID: 28555425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspective: The precision-oncology illusion.
    Prasad V
    Nature; 2016 Sep; 537(7619):S63. PubMed ID: 27602743
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical trials in the era of personalized oncology.
    Maitland ML; Schilsky RL
    CA Cancer J Clin; 2011; 61(6):365-81. PubMed ID: 22034206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Problematic Biomarker Trial Design.
    Freidlin B; Korn EL
    J Natl Cancer Inst; 2022 Feb; 114(2):187-190. PubMed ID: 34289052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.
    Raghav KP; Mahajan S; Yao JC; Hobbs BP; Berry DA; Pentz RD; Tam A; Hong WK; Ellis LM; Abbruzzese J; Overman MJ
    J Clin Oncol; 2015 Nov; 33(31):3583-90. PubMed ID: 26304898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision oncology: the intention-to-treat analysis fallacy.
    Sicklick JK; Kato S; Okamura R; Kurzrock R
    Eur J Cancer; 2020 Jul; 133():25-28. PubMed ID: 32422506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Oncology Care Model at 5 Years-Value-Based Payment in the Precision Medicine Era.
    Mullangi S; Schleicher SM; Parikh RB
    JAMA Oncol; 2021 Sep; 7(9):1283-1284. PubMed ID: 34196666
    [No Abstract]   [Full Text] [Related]  

  • 16. Entering the era of precision medicine in pediatric oncology.
    Hadjadj D; Deshmukh S; Jabado N
    Nat Med; 2020 Nov; 26(11):1684-1685. PubMed ID: 33077957
    [No Abstract]   [Full Text] [Related]  

  • 17. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug development in the era of precision medicine in oncology-Clues beyond randomization.
    du Rusquec P; Filleron T; Le Tourneau C
    Chin Clin Oncol; 2021 Jun; 10(3):23. PubMed ID: 33977726
    [No Abstract]   [Full Text] [Related]  

  • 19. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
    Tao JJ; Schram AM; Hyman DM
    Annu Rev Med; 2018 Jan; 69():319-331. PubMed ID: 29120700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision medicine strategies in oncology: mixed approaches to matched therapies.
    Borcoman E; Le Tourneau C
    Future Oncol; 2018 Jan; 14(2):105-109. PubMed ID: 29224361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.